Venture Capital

With new funding, Major Medical Devices is advancing a novel AAA repair device that uses arm access, promising safer procedures and wider patient eligibility.

With a new $1.6B valuation led by T. Rowe Price, Hadrian is scaling its AI-powered factories to spearhead America's industrial and defense resurgence.

After a year of scrutiny, a former Urban League leader invests in the aspiring minority-controlled stock exchange, validating its mission for structural change.

With promising data in hard-to-treat cancers, iOnctura's lead drug, roginolisib, is set to make waves at the top healthcare investment forum.

EpicQuest Education's CES award highlights its AI university plans, but a closer look reveals a complex picture of innovation, market hype, and financial risk.

With a key FDA decision looming, Orca Bio's massive new funding aims to commercialize a therapy that could make curative transplants safer for more patients.

With a massive $200M Series A and a promising Phase 2 drug, new biotech AirNexis aims to reshape the multi-billion dollar COPD treatment landscape.

With a major investment from Santé Ventures, Brado AI is deploying conversational AI to guide patients and ease provider burdens. Here’s what it means.

With 11 straight quarters of growth and a focus on 'Physical AI,' lidar leader Ouster is set to detail its ambitious strategy for institutional investors.

After a major business sale, Elutia is launching NXT-41x, an antibiotic biomatrix designed to combat the high rate of infection in breast reconstruction.

With new trials in myositis and pediatrics, Cartesian Therapeutics pioneers an outpatient cell therapy, moving beyond cancer to treat chronic autoimmune diseases.

With record revenue and a bold AI strategy, Opera heads to a key investor conference. Can its 'agentic' browsers redefine the web and win market share?

Biocytogen and Acepodia are expanding their partnership to create next-gen ADCs with two targets and two warheads, aiming to defeat drug-resistant cancers.

With new funding and a veteran biotech leader, Montreal's Find Therapeutics advances its first-in-class therapy aimed at reversing nerve damage in MS.

The biotech firm now expects Phase 2 results in Q3 2026, accelerating hope for new CNS treatments and signaling strong operational momentum to investors.

Thousands of parents will explore a burgeoning marketplace of school options in Las Vegas, from public charters to private academies, amid new state policies.

Ocugen heads to a top investor conference with a bold plan for its gene-agnostic therapy, aiming to treat blindness and secure its future in a crowded market.

ChipMOS reports stunning 20.8% Q4 growth, highlighting a memory chip frenzy fueled by AI and datacenters. Is this the start of a new tech supercycle?

Backed by CRISPR pioneers and $16M, a new biotech aims to make personalized gene therapies a scalable reality for millions with rare genetic disorders.

With support from a bipartisan alliance, nonprofit newsroom Votebeat is scaling up its expert reporting to fight election misinformation and bolster trust.